About ascentage pharma group international co ltd - ASPHF
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
ASPHF At a Glance
Ascentage Pharma Group International Co., Ltd.
Suzhou Industrial Park
Suzhou, Jiangsu 215000
| Phone | 86-512-85557777 | Revenue | 79.87M | |
| Industry | Pharmaceuticals: Major | Net Income | -172,884,187.14 | |
| Sector | Health Technology | Employees | 767 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ASPHF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 29.933 |
| Price to Book Ratio | 13.168 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -14.835 |
| Enterprise Value to Sales | 29.087 |
| Total Debt to Enterprise Value | 0.122 |
ASPHF Efficiency
| Revenue/Employee | 104,129.114 |
| Income Per Employee | -225,403.112 |
| Receivables Turnover | 1.853 |
| Total Asset Turnover | 0.172 |
ASPHF Liquidity
| Current Ratio | 1.792 |
| Quick Ratio | 1.774 |
| Cash Ratio | 1.503 |
ASPHF Profitability
| Gross Margin | 79.132 |
| Operating Margin | -211.138 |
| Pretax Margin | -215.349 |
| Net Margin | -216.465 |
| Return on Assets | -37.236 |
| Return on Equity | -153.182 |
| Return on Total Capital | -36.472 |
| Return on Invested Capital | -75.837 |
ASPHF Capital Structure
| Total Debt to Total Equity | 150.103 |
| Total Debt to Total Capital | 60.016 |
| Total Debt to Total Assets | 49.997 |
| Long-Term Debt to Equity | 57.173 |
| Long-Term Debt to Total Capital | 22.86 |